Company news
Chemocentryx Inc. (NASDAQ:CCXI) news
Chemocentryx Inc. news releases on 6ix. Latest, Jul 23, 2026: Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief…
Press releases & updates
Agility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial Officer
July 23, 2026
Agility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
July 14, 2026
Agility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XI
June 24, 2026
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026
February 5, 2026
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
October 16, 2022
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 4, 2022
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
August 23, 2022
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
July 4, 2022
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 5, 2022
ChemoCentryx Announces Changes to its Board of Directors
May 30, 2022
ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis Suppurativa
May 17, 2022
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
May 4, 2022
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
April 27, 2022
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
April 12, 2022
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
February 28, 2022
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
January 18, 2022
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 8, 2021
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
October 10, 2021
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
October 7, 2021
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
September 26, 2021
ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights
August 8, 2021
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
July 5, 2021
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
June 7, 2021
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
May 5, 2021
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
April 28, 2021
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
April 6, 2021
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
March 7, 2021
ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
February 23, 2021
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
February 16, 2021
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
December 20, 2020
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
November 8, 2020
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
November 5, 2020
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
October 27, 2020
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
September 16, 2020
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
August 9, 2020
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
July 8, 2020
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
June 23, 2020
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 14, 2020
ChemoCentryx Prices Public Offering of Common Stock
June 9, 2020
ChemoCentryx Announces Proposed Public Offering of Common Stock
June 9, 2020
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
May 17, 2020
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
May 10, 2020
ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
January 8, 2020
ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights
November 3, 2019
ChemoCentryx to Host R&D Day on October 1, 2019
September 23, 2019